Bateman, Randall J.
Cummings, Jeffrey
Schobel, Scott
Salloway, Stephen
Vellas, Bruno
Boada, Mercè
Black, Sandra E.
Blennow, Kaj
Fontoura, Paulo
Klein, Gregory
Assunção, Sheila Seleri
Smith, Janice
Doody, Rachelle S.
Article History
Received: 25 July 2022
Accepted: 31 October 2022
First Online: 29 November 2022
Declarations
:
: The studies reviewed in this article were conducted globally across multiple sites. Each study was approved by individual institutional ethics committees or institutional review boards and conducted in accordance with the principles of the Declaration of Helsinki and good clinical practice. Written informed consent was obtained from each patient.
: Not applicable.
: RJB is a co-founder and on the scientific advisory board of C2N Diagnostics and reports research support from Abbvie; Avid Radiopharmaceuticals; Biogen; Centene; Eisai; Eli Lilly and Company; Genentech, Inc.; F. Hoffmann-La Roche; Janssen; and United Neuroscience. JC has provided consultation to Acadia, Alkahest, AriBio, Avanir, Axsome, Behren Therapeutics, Biogen, Cassava, Cerecin, Cortexyme, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Merck, Novo Nordisk, Ono, Otsuka, ReMYND, Resverlogix, Roche, Signant Health, United Neuroscience, and Unlearn AI pharmaceutical and assessment companies. Dr. Cummings owns the copyright of the Neuropsychiatric Inventory. S. Schobel was an employee and shareholder of F. Hoffmann-La Roche Ltd. at the time this work was completed. S. Salloway was the co-chair of the Investigator Steering Committee for the aducanumab phase 3 program, served as a site PI for the aducanumab and lecanemab phase 3 studies and the donanemab phase 2 trial, and was the project arm leader for gantenerumab in DIAN-TU. He has received consulting income from Biogen, Lilly, Roche, Genentech, Bolden, Amylyx, Prothena, and Eisai. He has no stock or royalties related to any medication in development. He serves on the planning committee for the National Disease Modifying Treatment and Diagnostic Registry Work Group and is a member of the ADRD Therapeutics Work Group. BV has provided consultation to Biogen, Eisai, Grifols, Novo Nordisk, Roche, and Lilly. MB receives fees from Lab. Servier and Lilly for consulting, as well as from Lilly, Nutricia, Roche, and Schwabe for lectures. She receives fees from Lilly, Biogen, Roche, and Schwabe for advisory boards. SEB reports receiving in-kind research support from Avid Radiopharmaceuticals and GE Healthcare, assisting in developing the ADVANCE Program, a Canadian physician webinar series on dementia sponsored by Biogen and has presented on neuroimaging. Dr. Black has also been an ad hoc consultant to Biogen, F. Hoffman La Roche, and Roche Canada. Dr. Black acknowledges grant support from the Canadian Institutes of Health Research, the NIH, Leducq Foundation, Dasman Institute, Alzheimer Drug Discovery Foundation, the Weston Foundation, the Ontario Brain Institute, Brain Canada, and the Heart and Stroke Foundation of Canada. KB has served as a consultant and at scientific advisory boards and/or data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. PF and GK are employees of F. Hoffman-La Roche and own stock or stock options in F. Hoffmann-La Roche Ltd. SSA is an employee of Genentech, Inc., part of F. Hoffmann-La Roche. JS is an employee of Roche Products Ltd. and owns stock options in F. Hoffmann-La Roche Ltd. RD is an employee of Genentech, Inc., part of F. Hoffmann-La Roche Ltd., and owns stock in F. Hoffmann-La Roche Ltd.